Vertex Pharmaceuticals (VRTX) Income from Non-Controlling Interests (2011 - 2018)

Vertex Pharmaceuticals' Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$25.4 million for Q4 2018.

• In Q4 2018, Income from Non-Controlling Interests fell 1794.27% year-over-year to -$25.4 million; the TTM figure through Sep 2019 stood at -$25.4 million (down 248.38% YoY), while the FY2018 annual figure was -$9.8 million, up 94.3% from the prior year.
• Income from Non-Controlling Interests for Q4 2018 stood at -$25.4 million, down from -$290000.0 in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $28.4 million in Q2 2016, with the low at -$188.3 million in Q3 2017.
• The 5-year median for Income from Non-Controlling Interests is -$98000.0 (2015), against an average of -$10.7 million.
• The sharpest annual moves came in 2016 and 2017: Income from Non-Controlling Interests jumped 5741.84% in 2016, then slumped 26956.75% in 2017.
• Vertex Pharmaceuticals' Income from Non-Controlling Interests stood at $4.2 million in 2014, then plunged by 122.39% to -$938000.0 in 2015, then sank by 452.88% to -$5.2 million in 2016, then jumped by 128.94% to $1.5 million in 2017, then slumped by 1794.27% to -$25.4 million in 2018.
• Business Quant data shows VRTX's Income from Non-Controlling Interests at -$25.4 million in Q4 2018, -$290000.0 in Q3 2018, and -$1.1 million in Q2 2018.